STOCK TITAN
  1. Home
  2. News
  3. OM

Outset Medical Inc - OM STOCK NEWS

Welcome to our dedicated news page for Outset Medical (Ticker: OM), a resource for investors and traders seeking the latest updates and insights on Outset Medical.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Outset Medical's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Outset Medical's position in the market.

News
Outset Medical to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024
Rhea-AI Summary
Outset Medical, Inc. (Nasdaq: OM) will announce its first quarter 2024 financial results on May 8, 2024. The company will host a conference call to discuss the results, led by Leslie Trigg, Chair, and CEO, and Nabeel Ahmed, CFO.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.11%
Tags
conferences earnings
-
News
Outset Medical and U.S. Renal Care Announce Multi-Year Agreement to Accelerate and Grow Home Dialysis Across the U.S.
Rhea-AI Summary
Outset Medical and U.S. Renal Care have announced a multi-year agreement to accelerate home dialysis across the U.S. The agreement aims to provide patients with innovative home dialysis using the Tablo Hemodialysis System. Studies show that home dialysis can improve the mental and physical health of patients with end-stage kidney disease. Only 3% of the ESKD population currently performs home hemodialysis due to historical complexities. The partnership allows U.S. Renal Care to offer the Tablo system in 33 states, making dialysis more accessible and convenient for patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.85%
Tags
none
-
News
Outset Medical Partners with American Nephrology Nurses Association to Support Nephrology Nursing and Patient Care
Rhea-AI Summary
Outset Medical partners with American Nephrology Nurses Association to support nephrology nursing and patient care. The collaboration aims to empower and educate nephrology nurses, enhancing patient outcomes in kidney disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.49%
Tags
partnership
News
Outset Medical Announces Appointment of Medical Technology Veteran Brent D. Lang to its Board of Directors
Rhea-AI Summary
Outset Medical, Inc. (OM) appoints medical technology veteran Brent D. Lang to its board of directors. Mr. Lang brings extensive healthcare expertise, including growing software-enabled business models. Katie M. Szyman steps down to prepare for a new role. Mr. Lang's background in leadership positions at Vocera and other companies makes him a valuable addition to the Outset board.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.7%
Tags
management
-
News
Outset Medical to Present at the 44th Annual TD Cowen Health Care Conference
Rhea-AI Summary
Outset Medical, Inc. (OM) will present at the 44th annual TD Cowen Health Care conference to showcase their innovative dialysis technology. The presentation will be on March 5, 2024, at 1:30 p.m. Eastern time. Investors can access the webcast on the Outset website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.61%
Tags
conferences
-
News
Outset Medical Reports Fourth Quarter and Full Year 2023 Financial Results
Rhea-AI Summary
Outset Medical, Inc. (OM) reported fourth-quarter revenue of $30.5 million, with a 13% increase in 2023 revenue compared to 2022. The company achieved a 900 basis point increase in gross margin, reaching 25.3% in Q4. Outset's recurring revenue exceeded 50% of total revenue, with a Tablo installed base of 5,350 consoles. Despite a decrease in Q4 revenue, there was growth in service and other revenue.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.23%
Tags
earnings
News
ROLLINS, INC. ANNOUNCES CHANGES TO ITS BOARD OF DIRECTORS
Rhea-AI Summary
Rollins, Inc. announces the nomination of Dale Jones for election to the Board of Directors at the 2024 Annual Meeting, while Lead Director Jerry Nix is set to retire. Dale Jones, currently the CEO of MagnaVista Partners, has extensive experience in leadership development consulting. Jerry Nix, who has been the Lead Director since 2021, will retire post the annual meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.68%
Tags
management
-
News
Outset Medical to Report Fourth Quarter and Full-Year 2023 Financial Results on Wednesday, February 21, 2024
Rhea-AI Summary
Outset Medical, Inc. (OM) will release financial results for Q4 and full-year 2023 on February 21, 2024. Leslie Trigg, CEO, and Nabeel Ahmed, CFO, will host a conference call to discuss financial and operating results. The conference call will be available via webcast on the 'Investors' section of the Outset website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.76%
Tags
conferences earnings
-
News
Outset Medical Reports Unaudited Fourth Quarter and 2023 Revenue, Provides 2024 Revenue and Non-GAAP Gross Margin Guidance
Rhea-AI Summary
Outset Medical, Inc. (OM) reported unaudited revenue for Q4 and fiscal year ended December 31, 2023, with revenue totaling $30.5 million in Q4 and $130 million for the year, a 13% increase from 2022. The period-end installed base increased 34% year-over-year to approximately 5,350 Tablo Hemodialysis Systems, with consumable revenue growing nearly 50% year-over-year. Outset's cash position is now approximately $270 million. 2024 revenue is expected to be between $145 million to $153 million, growing 12% to 18% over unaudited revenue for 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.41%
Tags
none
News
Outset Medical to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Outset Medical, Inc. (OM) to present at J.P. Morgan Healthcare conference on January 8, 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.24%
Tags
conferences
Stock OM logo
Outset Medical Inc

Nasdaq:OM

OM Rankings

#4102 Ranked by Market Cap
#5305 Ranked by Stock Gains
N/A Ranked by Dividends

OM Stock Data

103.54M
49.62M
3.97%
104.48%
16.55%
Electromedical and Electrotherapeutic Apparatus Manufacturing
Manufacturing
Link
US
San Jose

About OM

outset is a pioneering medical technology company that always puts the patient before the machine. our human-centered model is designed to dramatically improve not only the care experience – for patients, families, providers and physicians alike – but also cost-efficiencies for providers. and to achieve this goal, we brought together the most dedicated, creative minds from dialysis with the most dedicated, creative minds from other healthcare fields, in the belief that cross-fertilization – along with hard work – is the surest path to invention. because we believe a dialysis machine should be as easy to use as an everyday consumer product, tablo was designed with simplicity in mind. one example is tablo’s touchscreen display, which offers step-by-step pictures and conversational instructions that make it hard to mess up no matter how new a patient, or caregiver, may be to dialysis. and with simplicity comes speed. we’ve set out to give people their time back. tablo dramatically reduces